US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VanEck Vectors Coal ETF

94.92

0.0000

Volume:- -

Turnover:- -

Market Cap:35.12M

PE:- -

High:94.92

Open:94.92

Low:94.92

Close:94.92

52wk High:111.00

52wk Low:54.10

Shares:370.00K

Float Shares:370.00K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Legendary Space will host a global livestream focusing on the utility of the platform's token SIG.

Community Announcement: The social protocol Firefly will be releasing its token soon

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Nansen Data: Meme KOL "pow" Records Highest Realized Profit of $497,000 in Past 7 Days

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Press Release: Abivax Presents First Quarter 2025 Financial Results

Press Release: BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

Press Release: Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Press Release: BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Press Release: Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KOL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KOL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KOL\",,,,,undefined,":{"symbol":"KOL","market":"US","secType":"STK","nameCN":"VanEck Vectors Coal ETF","latestPrice":94.92,"timestamp":1607979600000,"preClose":94.92,"halted":4,"volume":0,"delay":0,"floatShares":370000,"shares":370000,"eps":0,"marketStatus":"Delisted","change":0,"latestTime":"12-14 16:00:00 EST","open":94.92,"high":94.92,"low":94.92,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1757318400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":94.92,"sharesOutstanding":370000,"nav":95.75227,"aum":35428340.72,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KOL\",,,,,undefined,":{"symbol":"KOL","floatShares":370000,"roa":"--","roe":"--","lyrEps":0,"shares":370000,"dividePrice":0,"high":94.92,"amplitude":0,"preClose":94.92,"low":94.92,"week52Low":54.099,"pbRate":"--","week52High":111,"institutionHeld":0,"latestPrice":94.92,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":94.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KOL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-12-15","symbol":"KOL","reason":null,"defaultRemindTime":1608042600000,"announcedDate":"2020-12-04","type":"delisting","dateTimestamp":1608008400000},{"market":"US","date":"2020-12-11","symbol":"KOL","amount":3.2432,"defaultRemindTime":1607697000000,"name":"Market Vectors-Coal ETF","payableDate":"2020-12-14","currency":"USD","type":"dividend","dateTimestamp":1607662800000},{"market":"US","date":"2020-04-15","symbol":"KOL","type":"split","dateTimestamp":1586923200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2019-12-23","symbol":"KOL","amount":0.939,"name":"Market Vectors-Coal ETF","payableDate":"2019-12-24","currency":"USD","type":"dividend","dateTimestamp":1577077200000},{"market":"US","date":"2018-12-20","symbol":"KOL","amount":0.824,"name":"Market Vectors-Coal ETF","currency":"USD","type":"dividend","dateTimestamp":1545282000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KOL\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-20","recordDate":null,"paymentDate":null,"value":0.824,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":null,"value":0.939,"currency":"USD"},{"executeDate":"2020-12-11","recordDate":"2020-12-14","paymentDate":null,"value":3.2432,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KOL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KOL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2565511967","title":"Legendary Space will host a global livestream focusing on the utility of the platform's token SIG.","url":"https://stock-news.laohu8.com/highlight/detail?id=2565511967","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565511967?lang=en_us&edition=fundamental","pubTime":"2025-09-06 19:53","pubTimestamp":1757159580,"startTime":"0","endTime":"0","summary":"BlockBeats News, September 6th, Legendary Space, a Web3 application ecosystem platform, will kick off a global English live broadcast as a key part of the \"Talking Web3\" Top 100 KOL series, co-broadcasting synchronously on global mainstream platforms such as Binance Live, Huobi Live, Gate, YouTube, and TikTok.This live broadcast will be attended by Legendary Space CEO Todd M. Brenn and Legendary Labs CPO Dr. Dora Tang, providing a comprehensive analysis of the ecological closed-loop and value proposition of their platform token $SIG.Key Highlights:$SIG, as the platform's native token, possesses fuel properties and a mining mechanism that runs through the entire process of game interaction, contract calls, and ecosystem incentives;A \"two-way holding\" mechanism between project parties and the platform, building a \"$SIG-bound Prosperity DAO\" model across multiple projects;A native token entry and exit + burning mechanism, complementing $SIG to form a dual-channel for token application and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"theblockbeats_live","url":"https://www.theblockbeats.info//en/flash/311049","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/311049","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["KOL","BK4200","BK4567","BK4585","IE00B5TLWC47.USD","BK4104","FAST","IE00BYQQ9H92.USD","SIG","IE00BFXG0V08.USD","BK4588"],"gpt_icon":0},{"id":"2565515771","title":"Community Announcement: The social protocol Firefly will be releasing its token soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2565515771","media":"Blockbeats","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565515771?lang=en_us&edition=fundamental","pubTime":"2025-09-06 16:01","pubTimestamp":1757145660,"startTime":"0","endTime":"0","summary":"BlockBeats News, September 6th, according to multiple KOL disclosures, the social protocol Firefly is set to release its token soon.It is reported that Firefly, a social protocol, is a core project in the Mask Network ecosystem. It is a decentralized social aggregator aimed at bridging Web2 and Web3 social networks, helping users explore on-chain activities and social interactions through a unified interface. Firefly was developed by Mask Network, launched around 2022, and spun off as an independent project from MaskDAO in February 2025 to further expand its team and innovation space.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"theblockbeats_live","url":"https://www.theblockbeats.info//en/flash/311036","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/311036","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["KOL"],"gpt_icon":0},{"id":"2562710725","title":"Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2562710725","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562710725?lang=en_us&edition=fundamental","pubTime":"2025-08-27 19:00","pubTimestamp":1756292400,"startTime":"0","endTime":"0","summary":"Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025SAN DIEGO, Aug.  27, 2025  (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/27/3139872/0/en/Skye-Bioscience-to-Host-Virtual-KOL-Event-and-Provide-Perspectives-on-Upcoming-CBeyond-Phase-2a-Topline-Clinical-Data-Readout.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4218","KOL","BK4181","BK4588","HST"],"gpt_icon":0},{"id":"2562346247","title":"Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108","url":"https://stock-news.laohu8.com/highlight/detail?id=2562346247","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562346247?lang=en_us&edition=fundamental","pubTime":"2025-08-25 21:00","pubTimestamp":1756126800,"startTime":"0","endTime":"0","summary":"– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan – Segment provides further insight into the need for more eff","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/25/3138511/0/en/Palisade-Bio-Releases-Virtual-Investor-KOL-Connect-Segment-on-FSCD-and-Lead-Candidate-PALI-2108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","IBD","BK4139","BK4007","KOL"],"gpt_icon":0},{"id":"1104406019","title":"Nansen Data: Meme KOL \"pow\" Records Highest Realized Profit of $497,000 in Past 7 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=1104406019","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104406019?lang=en_us&edition=fundamental","pubTime":"2025-08-20 15:42","pubTimestamp":1755675751,"startTime":"0","endTime":"0","summary":"According to Nansen data, renowned Meme KOL pow (address: H1gJR2…n8Dwo2) achieved a PnL of $1.22 million in Solana Meme trading over the past 7 days, with the highest realized profit reaching $497,000. The primary profit sources came from profit-taking on PUMP and PENGU tokens.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOL"],"gpt_icon":0},{"id":"2558602436","title":"IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2558602436","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558602436?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:05","pubTimestamp":1754942700,"startTime":"0","endTime":"0","summary":"Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked first revenue from first-generation GraftAssureIQ research-use-only kits; beg","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/11/3131238/0/en/IMDX-Reports-Q2-2025-Results-and-Momentum-Toward-GraftAssureDx-Launch.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INAQU","LU1481600234.SGD","LU1169589451.USD","BK4139","IMDX","LU1169590202.USD","LU2463526074.USD","IE00B3T34201.USD","LU1487256676.USD","KOL","BK4136","BK4585","LU1481599808.USD","IP","BK4588"],"gpt_icon":0},{"id":"2557596145","title":"Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557596145","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557596145?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:05","pubTimestamp":1754597100,"startTime":"0","endTime":"0","summary":"Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129636/0/en/Atea-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVIR","BK4007","KOL"],"gpt_icon":0},{"id":"2557599974","title":"Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557599974","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557599974?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:01","pubTimestamp":1754596860,"startTime":"0","endTime":"0","summary":"Reiterate top-line data readout from CBeyond Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in Skye’s CBeyondTM Phase 2a obesity trial extension study initiated Independen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129603/0/en/Skye-Bioscience-Reports-Second-Quarter-2025-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0267386448.USD","BK4006","IE00B1BXHZ80.USD","LU1363072403.SGD","IE00BZ1G4Q59.USD","LU0170899867.USD","LU2746668461.USD","SKYE","LU2746668974.SGD","IE00BHPRN162.USD","LU0971096721.USD","CMC","IE00BKVL7J92.USD","LU0149725797.USD","LU0882574139.USD","KOL","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2555205020","title":"IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2555205020","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555205020?lang=en_us&edition=fundamental","pubTime":"2025-07-31 04:05","pubTimestamp":1753905900,"startTime":"0","endTime":"0","summary":"iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined scoreData show significantly improved positive predictive value (PPV) for graft rejection, which ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/30/3124422/0/en/IMDX-World-Transplant-Congress-Late-Breaking-Data-Potentially-Sets-New-Bar-for-Predicting-Graft-Rejection-in-Kidney-Transplant-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4179","IMDX","BK4139","NGS","KOL"],"gpt_icon":0},{"id":"2555709120","title":"iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2555709120","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555709120?lang=en_us&edition=fundamental","pubTime":"2025-07-29 04:05","pubTimestamp":1753733100,"startTime":"0","endTime":"0","summary":"NASHVILLE, Tenn., July  28, 2025  (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will host a virtual key opinion leader (KOL) event on Friday, Augu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/28/3122825/0/en/iMDx-to-Host-Virtual-KOL-Event-to-Discuss-its-In-House-dd-cfDNA-Testing-for-Kidney-Transplant-Patients-on-August-15-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYQQ9H92.USD","BK4567","BK4104","KOL","BK4588","IE00B5TLWC47.USD","BK4218","IE00BFXG0V08.USD","BK4181","HST","BK4585","FAST"],"gpt_icon":0},{"id":"2550597929","title":"Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2550597929","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550597929?lang=en_us&edition=fundamental","pubTime":"2025-07-11 21:36","pubTimestamp":1752240960,"startTime":"0","endTime":"0","summary":"– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amylo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/11/3114044/0/en/Immix-Biopharma-Announces-Class-Leading-Safety-Profile-Allowing-Potential-Future-Indication-Expansion.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","KOL","ODD","IE0009354923.USD"],"gpt_icon":0},{"id":"2549530799","title":"Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2549530799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549530799?lang=en_us&edition=fundamental","pubTime":"2025-07-07 21:35","pubTimestamp":1751895300,"startTime":"0","endTime":"0","summary":"– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication –  – NEXICART-2 interim result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/07/3111088/0/en/Immix-Biopharma-Announces-Accelerated-NEXICART-2-Clinical-Trial-Progress-in-relapsed-refractory-AL-Amyloidosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4572","PRGS","BK4183","IE0034390439.USD","IE0009354923.USD","IE00B19Z6F94.USD","LU1169590202.USD","KOL","ODD","LU1169589451.USD","LU2065732104.USD","BK4097","BK4104","AL"],"gpt_icon":0},{"id":"2549346145","title":"KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)","url":"https://stock-news.laohu8.com/highlight/detail?id=2549346145","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549346145?lang=en_us&edition=fundamental","pubTime":"2025-07-07 20:00","pubTimestamp":1751889600,"startTime":"0","endTime":"0","summary":"ARLINGTON, Mass., July  07, 2025  (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovativ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/07/3110987/0/en/KALA-BIO-to-Host-Virtual-Key-Opinion-Leader-KOL-Event-to-Discuss-the-Potential-of-KPI-012-for-the-Treatment-of-Persistent-Corneal-Epithelial-Defect-PCED.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4007","HST","BK4218","BK4585","BIO","KOL","LU1169590202.USD","LU1169589451.USD","BK4181","BK4588","BK4139","KALA"],"gpt_icon":0},{"id":"2540718760","title":"Press Release: Abivax Presents First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2540718760","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540718760?lang=en_us&edition=fundamental","pubTime":"2025-06-03 04:00","pubTimestamp":1748894400,"startTime":"0","endTime":"0","summary":"PARIS, France, June 2, 2025, 10:00 p.m. CEST -- Abivax SA  , a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial results for the quarter ended March 31, 2025.Abivax provided the following updates on its business and operational goals in press releases published:. -- On January 9, 2025 in a press release titled \"Abivax Achieves Key. Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at. 2025 European Crohn's and Colitis Organization 20th Annual Congress\". Reports with the French and U.S. Securities Regulatory Agencies\". -- On April 22, 2025 in a press release titled \"Abivax Announces Annual. General Meeting Details as Company Advances Toward Key 2025 Value-Driving. of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately. of which Sales and Marketing costs      ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4116","KOL","CD"],"gpt_icon":0},{"id":"2535100128","title":"Press Release: BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535100128","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535100128?lang=en_us&edition=fundamental","pubTime":"2025-05-15 18:30","pubTimestamp":1747305000,"startTime":"0","endTime":"0","summary":"In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis . BX004 Phase 2b study in Cystic Fibrosis  on track to report topline results in Q1 2026. In April 2025, shareholders approved exercise of warrants issued in $12 million in financings announced in February 2025; funds expected to provide runway through topline Phase 2b results for BX004 trial. The Company will host a conference call and webcast today at 2:00 PM ET. -- Key highlights from the Phase 2 trial results incl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","PHGE","BK4568","BK4086","BK4588","TM","BK4585","CF","KOL","PAR","BK4099","BK4139","BK4093","BK4555","APT","BK4157","BK4604"],"gpt_icon":0},{"id":"2535781452","title":"Press Release: Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535781452","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535781452?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:11","pubTimestamp":1747080660,"startTime":"0","endTime":"0","summary":"Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV. Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver  Congress 2025. Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14, 2025, at 10:00 AM ET. The Company's combination regimen of bemnifosbuvir , a nucleotide analog polymerase inhibitor, and ruzasvir , an NS5A inhibitor, is in Phase 3 development for the treatment of hepatitis C virus .Atea will host a virtual key opinion leader  investor event with a panel of HCV experts and prescribers on Wednesday, May 14, 2025, at 10:00 AM ET. To register, click here.This investor event will include an expert panel of several leaders in hepatology, gastroenterology, infectious diseases, and HCV treatments in the US, Canada and Europe. These experts and prescribers will discuss the cur","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVIR","KOL","BK4007"],"gpt_icon":0},{"id":"2525993228","title":"Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2525993228","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525993228?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is exp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057520/0/en/Opus-Genetics-Announces-One-Month-Clinical-Data-from-Pediatric-Patient-in-Phase-1-2-Trial-of-OPGx-LCA5-Gene-Therapy-in-Inherited-Retinal-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","IRD","LCA","LU0971096721.USD","BK4588","LU1363072403.SGD","CMC","BK4007","BK4613","KOL","IE00BKVL7J92.USD","LU0170899867.USD","IE00BZ1G4Q59.USD","BK4585","IE00B1BXHZ80.USD","SAP","IE00BHPRN162.USD","BK4023","LU0149725797.USD","LU0267386448.USD","LU0882574139.USD","BK4528"],"gpt_icon":0},{"id":"2523917894","title":"Press Release: BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917894","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917894?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"Conference call and webcast at 8:30 a.m. Eastern Time today. NEW YORK, March 31, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, and provided a corporate update.-- December 30, 2024: Issued a letter to shareholders summarizing key. -- December 11, 2024: Hosted a key opinion leader  webinar featuring. Dr. Terry Heiman-Patterson, from the Lewis Katz School of Medicine. at Temple University. Dr. Heiman-Patterson discussed the current. treatment landscape and advances for patients with ALS . The replay. can be accessed on the corporate website here.-- November 11, 2024: Announced a strategic partnership with Pluri to. support manufacturing for the Phase 3b NurOwn trial, enhancing. -- October 30, 2024: Regained compliance with Nasdaq's minimum bid price. requirement, maintaining continued listing on the Nasdaq Capital Mar","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772840.SGD","BK4585","LU0106831901.USD","LU2089284900.SGD","LU2357305700.SGD","LU2089283258.USD","R","LU0149725797.USD","BK4006","CMC","LU0267386448.USD","LU0158827781.USD","LU0795875086.SGD","LU2347655156.SGD","LU0314104364.USD","LU0158827948.USD","LU2111349929.HKD","LU0795875169.SGD","IE00BHPRN162.USD","BK4581","BK4504","KOL","LU0971096721.USD","IE00B1BXHZ80.USD","LU1732800096.USD","LU2271345857.HKD","LU1720051017.SGD","LU1363072403.SGD","LU2133065610.SGD","BK4022","BK4232","LU1732799900.SGD","LU1162221912.USD","LU1668664300.SGD","BK4127","LU0320765646.SGD","LU0106261372.USD","LU0098860793.USD","BK4588","LU0912757837.SGD","BK4516","LU2028103732.USD","LU1548497426.USD","IE00BZ1G4Q59.USD","LU2023251221.USD","BCLI","LU1989772923.USD","LENZ","LU1720051108.HKD","BK4534"],"gpt_icon":0},{"id":"2522402225","title":"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2522402225","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522402225?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertensionRADNOR, Pa., March  25, 2025  (GL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/25/3048654/0/en/Mineralys-Therapeutics-to-Host-KOL-Call-to-Discuss-Clinical-Data-from-Launch-HTN-and-Advance-HTN-Pivotal-Trials-Tuesday-April-1-2025-at-8-00-AM-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","MLYS","BK4218","KOL","HST","BK4144","BK4181","AM","BK4561","BK4581","BK4590","ET","BK4588","BK4585"],"gpt_icon":0},{"id":"2522707656","title":"Press Release: Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707656?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:05","pubTimestamp":1742846700,"startTime":"0","endTime":"0","summary":"Phase 3 NEAT clinical trial exceeds 50% enrollment with new study site activations expected to accelerate screenings and randomization. Existing cash position of $40.8 million expected to provide operating runway through Phase 3 topline results into 2026. Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the fiscal year ended December 31, 2024.Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, \"Our Phase 3 pivotal NEAT clinical trial has exceeded 50% enrollment with 71 participants screened and 61 randomized. Recent and upcoming new site activations are expected to accelerate enrollment through our target completion date in the second quarter of 2025. Assuming target enrollment completion, topline results from the NEAT study are anticipated in the fou","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","QNCX","MAA","BK4139","BK4215","CNS","LENZ","KOL","BK4135"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}]}}